TY - JOUR
T1 - The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial
T2 - Spirometry Outcomes
AU - Anzueto, Antonio
AU - Wise, Robert
AU - Calverley, Peter
AU - Dusser, Daniel
AU - Tang, Wenbo
AU - Metzdorf, Norbert
AU - Dahl, Ronald
N1 - Funding Information:
This study was funded by Boehringer Ingelheim. Writing assistance was provided by Sarah J. Petit of PAREXEL, funded by Boehringer Ingelheim. Data have been reported in part in the primary data publication [7] and at the CHEST/ACCP congress 2013 [21].
Publisher Copyright:
© 2015 Anzueto et al.
PY - 2015/9/15
Y1 - 2015/9/15
N2 - Background: Tiotropium Safety and Performance in Respimat® (TIOSPIR®) compared the safety and efficacy of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIR® was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium Respimat® 5 μg (n = 461), 2.5 μg (n = 464), or tiotropium HandiHaler® 18 μg (n = 445). Adjusted mean trough FEV1 (average 24-120 weeks) was 1.285, 1.258, and 1.295L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups (difference versus HandiHaler® [95% CI]: -10 [-38, 18] mL for Respimat® 5 μg and, -37 [-65, -9] mL for Respimat® 2.5 μg); achieving noninferiority to tiotropium HandiHaler® 18 μg for tiotropium Respimat® 5 but not for 2.5 μg (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups. The rates of FEV1 decline over 24 to 120weeks were similar for the three treatment arms (26, 40, and 34mL/year for the tiotropium Respimat® 5- μg, 2.5- μg, and HandiHaler® 18- μg groups). The rate of FEV1 decline in GOLD I + II patients was greater than in GOLD III + IV patients (46 vs. 23mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIR® spirometry substudy showed that tiotropium Respimat® 5 μg was noninferior to tiotropium HandiHaler® 18 μg for trough FEV1, but Respimat® 2.5 μg was not. Tiotropium Respimat® 5 μg provides similar bronchodilator efficacy to tiotropium HandiHaler® 18 μg with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. Trial registration:NCT01126437 .
AB - Background: Tiotropium Safety and Performance in Respimat® (TIOSPIR®) compared the safety and efficacy of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIR® was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium Respimat® 5 μg (n = 461), 2.5 μg (n = 464), or tiotropium HandiHaler® 18 μg (n = 445). Adjusted mean trough FEV1 (average 24-120 weeks) was 1.285, 1.258, and 1.295L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups (difference versus HandiHaler® [95% CI]: -10 [-38, 18] mL for Respimat® 5 μg and, -37 [-65, -9] mL for Respimat® 2.5 μg); achieving noninferiority to tiotropium HandiHaler® 18 μg for tiotropium Respimat® 5 but not for 2.5 μg (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593L in the Respimat® 5 μg, 2.5 μg, and HandiHaler® 18 μg groups. The rates of FEV1 decline over 24 to 120weeks were similar for the three treatment arms (26, 40, and 34mL/year for the tiotropium Respimat® 5- μg, 2.5- μg, and HandiHaler® 18- μg groups). The rate of FEV1 decline in GOLD I + II patients was greater than in GOLD III + IV patients (46 vs. 23mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIR® spirometry substudy showed that tiotropium Respimat® 5 μg was noninferior to tiotropium HandiHaler® 18 μg for trough FEV1, but Respimat® 2.5 μg was not. Tiotropium Respimat® 5 μg provides similar bronchodilator efficacy to tiotropium HandiHaler® 18 μg with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. Trial registration:NCT01126437 .
UR - http://www.scopus.com/inward/record.url?scp=84941565154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941565154&partnerID=8YFLogxK
U2 - 10.1186/s12931-015-0269-4
DO - 10.1186/s12931-015-0269-4
M3 - Article
C2 - 26369563
AN - SCOPUS:84941565154
SN - 1465-9921
VL - 16
JO - Respiratory research
JF - Respiratory research
IS - 1
M1 - 107
ER -